Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B
Key facts
- Who runs it
- Xiamen Amoytop Biotech Co., Ltd.
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 60 people, planned
- Starts
- 31 Dec 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional, 4 groups
- Treatments tested
- ACT201 Injection
- PegIFNα-2b Injection
- Tenofovir Alafenamide Fumarate(TAF)
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Voluntarily participate in this trial and sign the informed consent form
- Aged 18 to 65 years (inclusive), male or female
- Body mass index (BMI) between 18 and 32 kg/m² (inclusive)
- HBsAg-positive or HBV DNA-positive for at least 6 months, or previous liver biopsy showing chronic HBV infection, or HBsAg-positive and anti-HBc IgM-negative at screening
- No prior treatment with nucleos(t)ide analogues or interferons for chronic hepatitis B within 6 months before screening
- HBsAg, HBeAg, HBV DNA and liver function indicators meet the protocol requirements
- Willing to use effective contraception and have no plan for pregnancy, sperm donation or oocyte donation
Who cannot take part
- Subjects with recent major trauma or major surgery, or those scheduled to undergo surgery
- Prior solid organ or bone marrow transplantation
- Prior or current use of prohibited medications
- Concomitant hematological diseases
- Participation in another clinical trial, or failure to complete the washout period specified in the protocol prior to this trial
- Presence of clinically significant uncontrolled abnormalities or other severe diseases other than chronic HBV infection
- History of other liver diseases
- History of liver cirrhosis
- Imaging suggestive of a suspected malignant hepatic lesion
- History of extrahepatic diseases potentially associated with HBV immune status
- Other diseases associated with vasculitis
- Infections (other than HBV) requiring systemic antiviral or antibacterial therapy at screening
- History of malignancy
- Presence or history of severe psychiatric disorders
- Severe retinopathy or other serious ophthalmic diseases
- History of allergy
- Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in this trial
- Abnormal laboratory findings
- Lactating female subjects or those with a positive serum pregnancy test at screening
- Past or current evidence of hepatic decompensation
- Abnormal QTcF interval
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, open-label, parallel-controlled phase Ib clinical trial, which aims to evaluate the safety and preliminary efficacy of ACT201 injection combined with standard-of-care therapy (PegIFNα, NAs) in treatment-naive participants with chronic hepatitis B. A total of 60 treatment-naive participants with chronic hepatitis B are planned to be enrolled and randomized Treatment Group 1, Treatment Group 2, Treatment Group 3 or Treatment Group 4 for treatment.
The 4 groups in the trial
- Group 1Treatment being tested
Treatment: ACT201 Injection, PegIFNα-2b Injection, and Tenofovir Alafenamide Fumarate(TAF)
- Group 2Treatment being tested
Treatment: ACT201 Injection, PegIFNα-2b Injection, and Tenofovir Alafenamide Fumarate(TAF)
- Group 3Treatment being tested
Treatment: ACT201 Injection, PegIFNα-2b Injection, and Tenofovir Alafenamide Fumarate(TAF)
- Group 4Treatment being tested
Treatment: ACT201 Injection and Tenofovir Alafenamide Fumarate(TAF)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Open-Label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B(CHB)
- Criteria questions
- Built from NCT07946757, who can take part
- Record updated
- 18 November 2026